A new study helps explain why the candidate vaccine used in the HVTN 505 clinical trial was not protective against HIV infection despite robustly inducing anti-HIV antibodies: the vaccine stimulated antibodies that recognized HIV as well as microbes commonly found in the intestinal tract, part of the body's microbiome.

Source: HVTN 505 vaccine induced antibodies nonspecific for HIV


David Cottle

UBB Owner & Administrator